Cannabis Laws in the United Kingdom

Legal framework

Cannabis is controlled under the Misuse of Drugs Act 1971, which classifies substances into Classes A, B and C. Cannabis was reclassified from Class B to Class C in 2004, then moved back to Class B in January 2009 following advice the government chose to accept — despite the Advisory Council on the Misuse of Drugs recommending it remain Class C ^[1][2]. It covers herbal cannabis, resin (hash), and cannabis oil (excluding compliant CBD products).

The Misuse of Drugs Regulations 2001 govern lawful uses. Cannabis-based products for medicinal use (CBPMs) were moved from Schedule 1 to Schedule 2 on 1 November 2018, allowing prescription by specialist doctors on the General Medical Council's Specialist Register ^[3].

The law applies uniformly across England, Wales, Scotland and Northern Ireland, though Scotland's separate prosecution system (the Crown Office and Procurator Fiscal Service) exercises its own discretion.

Penalties

Statutory maximums under the Misuse of Drugs Act 1971 for Class B offences ^[1]:

• Possession: up to 5 years imprisonment, an unlimited fine, or both.
• Supply or production: up to 14 years imprisonment, an unlimited fine, or both.
• Import/export: up to 14 years under the Customs and Excise Management Act 1979.

In practice, most first-time possession offences involving small quantities are dealt with by a cannabis warning (a non-statutory police disposal) or a Penalty Notice for Disorder (£90 fine) rather than arrest ^[4]. This is force-dependent and has been controversial: several forces have effectively de-prioritised possession enforcement, while others prosecute more actively. A conviction still counts as a criminal record and can affect employment, travel (notably to the US), and immigration status.

Medical cannabis

Since 1 November 2018, specialist doctors can prescribe unlicensed cannabis-based products for medicinal use ^[3]. Two licensed cannabis-derived medicines are also available:

• Epidyolex (cannabidiol) — for certain rare epilepsies.
• Sativex (nabiximols) — for MS-related spasticity.
• Nabilone — a synthetic cannabinoid for chemotherapy-induced nausea.

Despite the legal change, NHS prescribing of unlicensed CBPMs is extremely rare Strong evidence. NICE guidance (NG144, 2019, updated) recommends against routine use for chronic pain and takes a cautious view on other conditions due to limited high-quality evidence ^[5]. Most patients — estimates run to tens of thousands — access cannabis through private clinics, paying for consultations and monthly prescriptions out of pocket ^[6].

High-profile cases involving children with severe epilepsy (Alfie Dingley, Billy Caldwell) drove the 2018 rule change, but very few NHS prescriptions have followed even in similar cases.

CBD and hemp

CBD products sold to consumers are legal in the UK subject to several conditions. The Food Standards Agency classifies ingestible CBD as a novel food, meaning products require FSA authorisation to be sold legally; the FSA maintains a public list of products linked to validated applications ^[7].

Critically, finished consumer CBD products must not contain more than 1 mg of controlled cannabinoids (including THC and CBN) per container, per Home Office guidance — this is not a percentage limit and is stricter than the EU's approach ^[8]. Products exceeding this are legally controlled drugs regardless of CBD content. Products making medicinal claims also fall under MHRA regulation.

Hemp cultivation requires a Home Office licence. UK-grown hemp flower and leaf cannot legally be processed into CBD in the UK even from low-THC varieties — extract must come from imported material or from stalks and seeds only ^[8].

Enforcement in practice

Enforcement has drifted considerably from the letter of the law. Reported cannabis warnings and out-of-court disposals now handle most possession cases, and Home Office figures show a long-term decline in cannabis-related prosecutions and stop-and-searches producing prosecutions ^[4][9].

Some police and crime commissioners have piloted diversion schemes offering education instead of prosecution for personal-use possession (e.g., Thames Valley, West Midlands, Durham) ^[9]. In late 2022, the then-Home Secretary suggested reclassifying cannabis to Class A, but no such change occurred and cannabis remains Class B ^[10].

Driving with THC in your system is a separate offence under section 5A of the Road Traffic Act 1988, with a 2 µg/L blood THC limit — low enough that recent use will typically exceed it ^[11].

Cannabis 'social clubs' operating openly (a model tolerated in Spain) do not have legal recognition in the UK; participants can be prosecuted for possession, supply, or production regardless of any club membership.

Recent developments

• November 2018: CBPMs moved to Schedule 2, enabling specialist prescribing.
• 2019: NICE guideline NG144 published, with cautious recommendations on medical cannabis ^[5].
• 2021–2023: FSA novel food process narrows the legal CBD market; thousands of products removed from sale.
• March 2024: London Mayor Sadiq Khan's London Drugs Commission (chaired by Lord Falconer) continued reviewing cannabis policy; its findings recommended partial decriminalisation of possession of natural cannabis but stopped short of legalisation ^[12].

As of the last verification date, no legislation to decriminalise or legalise recreational cannabis has been introduced by the UK government.

Not legal advice

This article is informational only and is not legal advice. Laws change, enforcement varies by police force, and individual circumstances matter. If you are facing a criminal matter, seeking a medical prescription, or planning a business involving cannabis or CBD, consult a qualified solicitor or a regulated medical practitioner in the relevant UK jurisdiction.

Information last verified: June 2024. Check the Home Office, MHRA, and FSA websites for the current position before relying on anything here.

Sources

How this page was made